Chem. J. Chinese Universities

• Article • Previous Articles     Next Articles

Highly Chemo- and Stereoselective Synthesis of S-Glycosides from Euparin: Evaluation of Their α-Glucosidase Inhibitory Activity

YU Zhao, FU Zishuai, Zhang Ying, LI Linxuan*, LIU Zhaoxia*, YAO Hui, HUANG Nianyu, WANG Nengzhong*   

  1. College of Biological and Pharmaceutical Sciences, Hubei Key Laboratory of Natural Products Research and Development, China Three Gorges University
  • Received:2025-12-22 Revised:2026-01-15 Online First:2026-01-17 Published:2026-01-17
  • Contact: Lin-Xuan LI E-mail:lilinxuan@ctgu.edu.cn
  • Supported by:
    Supported by the National Natural Science Foundation of China(Nos. 22207063, 22501156), the Hubei Provincial Central Government Guided Local Science and Technology Development Project(Nos. 2024BSB016, 2025CSA093), the Hubei Provincial Natural Science Foundation of China(Nos. 2025AFD262, 2025AFB213), the 111 Project(D20015), and the Opening Funding of Hubei Key Laboratory of Natural Products Research and Development(China Three Gorges University, Nos. 2024NPRD03~2024NPRD05, 2025NPRD01)

Abstract: Herein, a novel S-glycoside derivatives were designed and synthesized using euparin as the aglycone. Employing a palladium-catalyzed strategy, 22 S-glycosides were efficiently synthesized under mild conditions with high chemoselectivity and stereoselectivity. Evaluation of the in vitro α-glucosidase inhibitory activities of these compounds showed that compounds 5a, 5d, and 7 exhibited potent inhibitory activity, with IC?? values of 2.7 μmol/L, 5.7 μmol/L, and 12.1 μmol/L, respectively. Molecular docking studies revealed that these active compounds bind to the active site of α-glucosidase through hydrogen bonds(with ASP382 and HIS326 residues) and π-π stacking interactions(with PHE144 residue), contributing to high binding affinity(docking score: -32.409 kJ/mol). This study provides a mild and efficient synthetic method for euparin-derived S-glycosides and identifies promising lead compounds for the development of novel anti-diabetic drugs.

Key words: Diabetes mellitus, Euparin, α-Glucosidase, S-Glycoside; Palladium catalysis

CLC Number: 

TrendMD: